Commonly available dietary supplements, herbs and medicines – do they pose a risk for liver health? Literature review in the context of the Polish population

Ewa Janczewska; Barbara Janota

doi:10.5114/ceh.2024.143063

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2024
vol. 10

Send email

Copy url:

Review paper

Commonly available dietary supplements, herbs and medicines – do they pose a risk for liver health? Literature review in the context of the Polish population

Ewa Janczewska

¹

,

Barbara Janota

²

ID Clinic, Mysłowice, Poland
Department of Basic Medical Sciences, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, Bytom, Poland

Clin Exp HEPATOL 2024; 10, 3: 145-149

DOI: https://doi.org/10.5114/ceh.2024.143063

Online publish date: 2024/09/30

Article file

- Commonly.pdf [0.09 MB]

Get citation

PlumX metrics:

1. Sandhu N, Navarro V. Drug-induced liver injury in GI practice. Hepatol Commun 2020; 4: 631-645.

2. Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury. Nat Rev Dis Primers 2019; 5: 58.

3. Ustawa z dnia 25 sierpnia 2006 r. o bezpieczeństwie żywności i żywienia. Dz.U. 2006 nr 171 poz. 1225. Available from: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=wdu20061711225

4. Navarro VJ, Khan I, Björnsson E, et al. Liver injury from herbal and dietary supplements. Hepatology 2017; 65: 363-373.

5. Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int 2019; 39: 31-41.

6. Nunes DRDCMA, Breton MC, Monteiro CSJ, et al. Drug induced liver injury: Perspective of the adverse drug reaction reports to the Portuguese pharmacovigilance system from 2010 to 2019. Healthcare (Basel) 2021; 9: 1630.

7. Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology 2023; 77: 1036-1065.

8. Floreani A, Bizzaro D, Shalaby S, et al. Special interest group gender in hepatology of the Italian Association for the Study of the Liver (AISF). Sex disparity and drug-induced liver injury. Dig Liver Dis 2023; 55: 21-28.

9. Raport NIK LLO.430.005.2021 Nr ewid. 160/2021/P/21/078/ LLO Wprowadzanie Do Obrotu Suplementów Diety. Available from: https://www.nik.gov.pl/plik/id,25355,vp,28114.pdf

10. Mishra S, Stierman B, Gahche JJ, et al. Dietary supplement use among adults: United States, 2017-2018. NCHS Data Brief 2021; 399: 1-8.

11. Rozporządzenie Ministra Zdrowia z dnia 23 marca 2011 r. w sprawie wzoru formularza powiadomienia o produktach wprowadzanych po raz pierwszy do obrotu na terytorium Rzeczypospolitej Polskiej, rejestru produktów objętych powiadomieniem oraz wykazu krajowych jednostek naukowych właściwych do wydawania opinii (Dz. U. z 2011 r. poz. 437, z późn.zm.). Available from: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20110800437

12. Rozporządzenie Ministra Zdrowia z dnia 9 października 2007 r. w sprawie składu i oznakowania suplementów diety (Dz. U. z 2018 r., poz. 1951). Available from: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=wdu20071961425

13. Dopuszczanie do obrotu suplementów diety, LLO.430.002.2016 Nr ewid. 195/2016/P/16/078/LLO. Available from: https://www.nik.gov.pl/plik/id,13031,vp,15443.pdf

14. Hsu CH, Tsai TH, Kao YH, et al. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr 2008; 27: 363-370.

15. Rozporządzenie Komisji (UE) 2022/2340 z dnia 30 listopada 2022 r. zmieniające załącznik III do rozporządzenia (WE) nr 1925/2006 Parlamentu Europejskiego i Rady w odniesieniu do ekstraktów zielonej herbaty zawierających 3-galusan (-) epigalokatechiny, available from: https://publications.europa.eu/resource/cellar/5155ee73-7158-11ed-9887-01aa75ed71a1.0018.03/DOC_1

16. Johnston DI, Chang A, Viray M, et al. Hepatotoxicity associated with the dietary supplement OxyELITE Pro™ - Hawaii, 2013. Drug Test Anal 2016; 8: 319-327.

17. Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, et al. Spanish DILI Registry; SLatinDILI Network. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther 2015; 41: 116-125.

18. Patil V, Jothimani D, Harika K, et al. Versatility of anabolic androgenic steroid-induced hepatotoxicity. J Clin Exp Hepatol 2022; 12: 216-221.

19. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Available from: https://pubmed.ncbi.nlm.nih.gov/31643176/

20. Teschke R, Danan G. Idiosyncratic drug-induced liver injury (DILI) and herb-induced liver injury (HILI): Diagnostic algorithm based on the quantitative Roussel Uclaf Causality Assessment Method (RUCAM). Diagnostics (Basel) 2021; 11: 458.

21. Bartnik P, Drozd M. Problem polipragmazji u osób w podeszłym wieku na przykładzie 62-letniej kobiety. Farm Pol 2019; 75: 486-489.

22. Weiner M, Tokarska-Rodak M, Bida A. Stosowanie leków przeciwbólowych w różnych grupach wiekowych z uwzględnieniem relacji międzypokoleniowych. Rozprawy Społeczne 2019; 13: 72-79.

23. Ustawa z dnia 7 kwietnia 2022 r. o wyrobach medycznych (Dz.U. z 2022 r., poz. 974). Available from: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20220000974

24. Garczewski B, Wiśniewski M, Waldman W, et al. Zatrucia paracetamolem leczone w pomorskim centrum toksykologii w latach 2010–2015. Medycyna Pracy 2019; 7 0(6):733–738.

25. Garczewski B, Wiśniewski M, Waldman W, Sein Anand J. Zatrucia paracetamolem leczone w Pomorskim Centrum Toksykologii w latach 2010–2015. Medycyna Pracy 2019; 70: 733-738.

26. Daly C, Griffin E, McMahon E, et al. Paracetamol-related intentional drug overdose among young people: a national registry study of characteristics, incidence and trends, 2007-2018. Soc Psychiatry Psychiatr Epidemiol 2021; 56: 773-781.

27. Chidiac A, Buckley A, Noghrehchi F, et al. Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease. Expert Opin Drug Metab Toxicol 2023; 19: 297-317.

28. Rotundo L, Pyrsopoulos N. Liver injury induced by paracetamol and challenges associated with intentional and unintentional use. World J Hepatol 2020; 12: 125-136.

29. Walczewska S, Wawrzyniak A. N-acetylcysteine in clinical practice – properties, use and adverse effects. Pediatr Med Rodz 2020; 16: 243-246.

Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.

Commonly available dietary supplements, herbs and medicines – do they pose a risk for liver health? Literature review in the context of the Polish population

Ewa Janczewska 1 , Barbara Janota 2

Ewa Janczewska

¹

,

Barbara Janota

²